For example, the expression of TROP2 on alveolar type 1 cells exceeded ERBB2 expression (1549.8 vs. 73.7 nmTP); however, the incidence of ILD with datopotamab deruxtecan was found to be much lower that the results of DESTINY-lung 01 for trastuzumab deruxtecan (11 vs. 26%). This evidence concerns the gene ERBB2 and interstitial lung disease.